inetetamab + pyrotinib + utidelone

Inetetamab + pyrotinib + utidelone is a combination regimen used primarily for the treatment of HER2-positive advanced or metastatic breast cancer. Inetetamab is a novel monoclonal antibody targeting human epidermal growth factor receptor 2 (HER2), developed in China, and is structurally similar to trastuzumab but with an optimized Fc region to enhance antibody-dependent cell-mediated cytotoxicity[3][8]. Pyrotinib is an irreversible small molecule tyrosine kinase inhibitor that targets multiple members of the ErbB family, including HER1 (EGFR), HER2, and HER4, thereby blocking downstream signaling pathways essential for tumor cell proliferation[6][9]. Utidelone is a microtubule-stabilizing agent of the epothilone class that binds to tubulin at a site distinct from taxanes; it overcomes taxane resistance and can cross the blood-brain barrier[7][10]. This combination has shown efficacy in patients with heavily pretreated or resistant metastatic breast cancer, particularly those with prior exposure to other anti-HER2 therapies.